Risk Factors
Women with ATM, CHEK2, or PALB2 mutations may benefit from starting annual breast cancer screening with MRI between the ages and 30 to 35 and an annual MRI and mammogram starting at age 40.
Rates of screening mammograms among women who’ve received breast cancer treatment have declined since 2009, especially among women ages 40 to 49.
A large study has found that bisphosphonates reduce the risk of distant breast cancer recurrence in postmenopausal women.
A large study suggests that there is no link between vitamin D and overall survival or disease-free survival in women diagnosed with breast cancer with a high risk of recurrence. Still, there are questions about the study.
A 10-minute breast MRI exam, also called Fast Breast MRI, found more cancers than 3D mammograms in women with dense breasts.
Two studies on NSAIDs and breast cancer suggest that these medicines may help reduce the risk of recurrence of hormone-receptor-positive breast cancer in overweight and obese women and may also reduce the risk of breast cancer spreading to the lymph nodes.
Study suggests that for some women adding a medium amount of soy to their diets turns on genes that can cause cancer to grow.
The genetic mutations that increase breast cancer risk, including mutations in the BRCA1, BRCA2, and PALB2 genes, are the same for both Black and white women, which means that currently available genetic tests are effective for Black women.
A new study shows that women who smoked and got radiation therapy to treat breast cancer had a much higher risk of lung cancer later on compared to women who got radiation and didn't smoke.
Many women overestimate the risk of DCIS coming back.
Hormone replacement therapy seems to significantly increase the risk of breast cancer coming back.
An experimental test may be able to help predict the risk of hormone-receptor-positive breast cancer, but it's not clear how useful the test is.
The analysis of several studies show the link between obesity and worse prognosis in women diagnosed with early-stage breast cancer isn't consistent.
New research suggests that ACE inhibitors, a type of blood pressure medicine, may increase the risk of breast cancer recurrence.
Research has found that being overweight or obese at diagnosis doesn't affect the survival of women diagnosed with metastatic breast cancer.
Research shows that women with an abnormal BRCA1 or BRCA2 gene who've been diagnosed with breast cancer have a higher risk of being diagnosed with a new, different cancer in the opposite breast compared to women without an abnormal BRCA1 or BRCA2 gene.
Diabetic women treated with metformin who have been diagnosed with HER2-positive, hormone-receptor-positive breast cancer have better outcomes, including overall survival, than similar women who were not treated with metformin.
Research suggests that postmenopausal women who eat a healthy diet after a breast cancer diagnosis are less likely to die from breast cancer or any other cause.
A study suggests that taking a multivitamin with minerals may benefit postmenopausal women diagnosed with breast cancer.
A meta-analysis found that smokers have a much higher risk of dying from lung cancer or a heart attack as a result of radiation therapy for breast cancer.
Women who did 5 hours of moderate exercise per week before being diagnosed with breast cancer were much less likely to have heart problems after treatment compared to women who exercised for less time.
A study suggests that genetic test results are not being clearly communicated to women and may be causing them to opt for breast cancer treatment that is more aggressive than they need.
A structured exercise program of aerobic and weight-bearing exercise reduced the risk of heart disease in overweight or obese women diagnosed with early-stage breast cancer.
Black women are 2.7 times more likely to be diagnosed with triple-negative breast cancer than white women, according to a study of risk factors in more than 198,000 women.